Reference Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

Ref Type
Authors R. S. Meehan, A. P. Chen, G. Helen O'Sullivan C., J. M. Collins, S.Kummar, L. Anderson, K. Ishii, J. Zlott, L. Rubinstein, Y. Horneffer, L. Juwara, W. Jeong, N. Takebe, R. J. Kinders, R. E. Parchment, J. H. Doroshow
Title A phase 1 trial of TRC102 (methoxyamine HCl) with temozolomide (TMZ) in patients with solid tumors and lymphomas.
Abstract Text J Clin Oncol 34, 2016 (suppl; abstr 2556)


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
TRC102 TRC102 0 0
Drug Name Trade Name Synonyms Drug Classes Drug Description
TRC102 methoxyamine HCL|TRC-102 TRC102 inhibits the base excision repair pathway, potentially resulting in increased sensitivity to chemotherapeutic agents and anti-tumor activity (J Clin Oncol 34, 2016 (suppl; abstr 2556)).
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown Advanced Solid Tumor not applicable Temozolomide + TRC102 Phase I Actionable In a Phase I trial, the combination of Temodar (temozolomide) and TRC102 demonstrated safety and preliminary activity in a patients with advanced solid tumors, with 4/37 patients demonstrating partial response and 11/37 patients achieving stable disease (J Clin Oncol 34, 2016 (suppl; abstr 2556)). detail...